Skip to content

Study · Randomized controlled trial · n = 114 · 2014

3 results

Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.

Beck DE, Sweeney WB, McCarter MD

International journal of colorectal disease21 Oct 2014Cited by 19 (Europe PMC)

PMID25331030 (opens in a new tab)DOI10.1007/s00384-014-2030-8 (opens in a new tab)PepBankPUB-25331030
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults after bowel resection, median time to first tolerated meal did not differ significantly between ipamorelin and placebo.

    In plain wordsAfter bowel surgery, ipamorelin did not significantly shorten the time to a first tolerated meal compared with placebo.

    Peptide
    Ipamorelin
    Outcome
    No significant changeTime to first tolerated solid meal
    Study

    n = 114

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    0.03-mg/kg twice daily · intravenous · postoperative day 1 to 7 or hospital dischargeAs given in this study (human).

    Measurements

    Median time to first tolerated meal
    25.3 h
    ipamorelin
    Median time to first tolerated meal
    32.6 h
    placebo

    Source sentences

    Summary
    Median time to first tolerated meal was 25.3 and 32.6 h in the ipamorelin and placebo groups, respectively (p = 0.15).
    3 context sentences
    Summary · context
    The key efficacy endpoint was time from first dose of study drug to tolerance of a standardized solid meal.
    Summary · context
    This proof-of-concept, phase 2, randomized study evaluated the safety and efficacy of the ghrelin-receptor agonist ipamorelin in the treatment of postoperative ileus following abdominal surgery (ClinicalTrials.gov NCT00672074).
    Summary · context
    The patients were adults undergoing small and large bowel resection by open or laparoscopic surgery.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults after bowel resection, ipamorelin did not differ significantly from placebo in the secondary efficacy analyses.

    In plain wordsAfter bowel surgery, ipamorelin did not differ significantly from placebo on the other efficacy measures.

    Peptide
    Ipamorelin
    Outcome
    No significant changeSecondary efficacy analyses
    Study

    n = 114

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    0.03-mg/kg twice daily · intravenous · postoperative day 1 to 7 or hospital dischargeAs given in this study (human).

    Source sentences

    Summary
    There were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses.
    2 context sentences
    Summary · context
    This proof-of-concept, phase 2, randomized study evaluated the safety and efficacy of the ghrelin-receptor agonist ipamorelin in the treatment of postoperative ileus following abdominal surgery (ClinicalTrials.gov NCT00672074).
    Summary · context
    The patients were adults undergoing small and large bowel resection by open or laparoscopic surgery.
  3. 03HumanRandomized controlled trialSafety outcome

    In adults after bowel resection, any treatment-emergent adverse event occurred in 87.5 % with ipamorelin and 94.8 % with placebo; no significance test was reported.

    In plain wordsAfter bowel surgery, 87.5 % of patients on ipamorelin and 94.8 % on placebo had at least one side effect.

    Peptide
    Ipamorelin
    Outcome
    Direction not reportedTreatment-emergent adverse events, any
    Study

    n = 114

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    0.03-mg/kg twice daily · intravenous · postoperative day 1 to 7 or hospital dischargeAs given in this study (human).

    Measurements

    Any treatment-emergent adverse event
    87.5%
    ipamorelin
    Any treatment-emergent adverse event
    94.8%
    placebo

    Source sentences

    Summary
    Overall incidence of any treatment-emergent adverse events was 87.5 % in the ipamorelin group and 94.8 % in placebo group.
    2 context sentences
    Summary · context
    This proof-of-concept, phase 2, randomized study evaluated the safety and efficacy of the ghrelin-receptor agonist ipamorelin in the treatment of postoperative ileus following abdominal surgery (ClinicalTrials.gov NCT00672074).
    Summary · context
    The patients were adults undergoing small and large bowel resection by open or laparoscopic surgery.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT00672074

Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus

Helsinn Therapeutics (U.S.), Incn = 117Apr 2008 to Dec 2009

Ileus

Trial pageClinicalTrials.govUpdated 14 Apr 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.